Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 4.0 | 3.0 |
Min SIP Amount | ₹500 | ₹100 |
Expense Ratio | 1.94 | 1.9 |
NAV | ₹412.20 | ₹39.22 |
Fund Started | 04 Jun 1999 | 12 Nov 2018 |
Fund Size | ₹3628.03 Cr | ₹3339.79 Cr |
Exit Load | Exit load of 0.50% if redeemed within 15 days | Exit load of 0.50% if redeemed within 1 month. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 26.82% | 26.07% |
3 Year | 23.52% | 21.30% |
5 Year | 27.07% | 27.21% |
1 Year
3 Year
5 Year
Equity | 96.55% | 96.87% |
Cash | 3.37% | 3.13% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 13.00% |
Max Healthcare Institute Ltd. | 6.22% |
Divi's Laboratories Ltd. | 6.05% |
Cipla Ltd. | 5.90% |
Lupin Ltd. | 5.19% |
Lonza Group Ag | 4.16% |
Mankind Pharma Ltd. | 4.15% |
Poly Medicure Ltd. | 3.60% |
Krishna Institute of Medical Sciences Ltd | 3.46% |
Jupiter Life Line Hospitals Ltd. | 3.45% |
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 10.59% |
Suven Pharmaceuticals Ltd. | 8.49% |
Cipla Ltd. | 8.20% |
Ipca Laboratories Ltd. | 8.14% |
Globus Medical Inc | 5.70% |
Illumina Inc. (USA) | 4.78% |
Alembic Pharmaceuticals Ltd. | 4.54% |
Gland Pharma Ltd. | 4.38% |
Apollo Hospitals Enterprise Ltd. | 4.07% |
Concord Biotech Ltd. | 3.87% |
Name | Tanmaya Desai | Jay Kothari |
Start Date | 27 Jun 2011 | 16 Mar 2018 |
Name
Start Date
Description | The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space. | The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. |
Launch Date | 04 Jun 1999 | 12 Nov 2018 |
Description
Launch Date